Financial Performance Summary
- Revenue: $2.7 billion (+13% YoY, +6.73% QoQ)
- Gross Profit: $2.34 billion (+11.23% YoY, +9.07% QoQ)
- Operating Income: $1.14 billion (+45.83% YoY, +18.48% QoQ)
- Net Income: $1.10 billion (+57.13% YoY, +13.50% QoQ)
- Diluted EPS: $4.21 (+56.62% YoY, +13.30% QoQ)
- Cash Position: $9.16 billion at quarter-end, down from $10.37 billion at the beginning of the period, reflecting increased investment in growth initiatives.
Key Ratio Highlights
- Current Ratio: 3.50
- Net Profit Margin: 40.92%
- Return on Equity: 5.93%
- Debt to Equity Ratio: 0.0389, demonstrating strong balance sheet health with minimal leverage.
Performance Insights: The revenue surge is sourced predominantly from sales of TRIKAFTA, with contributions from new markets and patient populations driving future growth prospects. Management emphasized strong pipeline progression, notably in the CF segment and pain management therapies.